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Abstract
Introduction and Objective COVID-19 is an ongoing, global public health crisis for which safe and effective treatments 
need to be identified. The benefit-risk balance for the use of lopinavir-ritonavir in COVID-19 needs to be monitored on an 
ongoing basis, therefore a systematic benefit-risk assessment was designed and conducted. A key objective of this study 
was to provide a platform for a dynamic systematic benefit-risk evaluation; although initially this evaluation is likely to 
contain limited information, it is required because of the urgent unmet public need. Importantly, it allows additional data to 
be incorporated as they become available, and re-evaluation of the benefit-risk profile.
Methods A systematic benefit-risk assessment was conducted using the Benefit-Risk Action Team (BRAT) framework. The 
exposure of interest was lopinavir-ritonavir treatment in severe COVID-19 compared to standard of care, placebo or other 
treatments. A literature search was conducted in PubMed and Embase to identify peer-reviewed papers reporting clinical out-
comes. Two clinicians constructed a value tree and ranked key benefits and risks in order of considered clinical importance.
Results We screened 143 papers from PubMed and 264 papers from Embase for lopinavir-ritonavir; seven papers were 
included in the final benefit-risk assessment. In comparison to standard of care, data for several key benefits and risks were 
identified for lopinavir-ritonavir. Time to clinical improvement was not significantly different for lopinavir-ritonavir in com-
parison to standard of care (hazard ratio 1.31, 95% confidence interval 0.95–1.80). From one study, there were fewer cases 
of acute respiratory distress syndrome with lopinavir-ritonavir compared with standard of care (13% vs 27%). There also 
appeared to be fewer serious adverse events with lopinavir-ritonavir (20%) vs standard of care (32%). Limited data were 
available for comparison of lopinavir-ritonavir to other treatments.
Conclusions Based on currently available data, there was no clear benefit for the use of lopinavir-ritonavir compared to stand-
ard of care in severe COVID-19. Risk data suggested a possible decrease in serious adverse events. There was a reduction 
in acute respiratory distress syndrome with lopinavir-ritonavir in one study. Overall, the benefit-risk profile for lopinavir-
ritonavir in severe COVID-19 cannot be considered positive until further efficacy and effectiveness data become available.
Key Points 
COVID-19 is a global pandemic, for which lopinavir-
ritonavir has been proposed as a possible treatment.
Based on currently available data, there is no clear 
benefit for the use of lopinavir-ritonavir compared to 
standard of care in severe COVID-19.
Ongoing clinical trial data can be incorporated into the 
framework when available to provide an updated benefit-
risk assessment.
 * Vicki Osborne 
 vicki.osborne@dsru.org
1 Drug Safety Research Unit, Bursledon Hall, Blundell Lane, 
Southampton SO31 1AA, UK
2 School of Pharmacy and Biomedical Sciences, University 
of Portsmouth, Portsmouth, UK
 V. Osborne et al.
1 Introduction
Coronaviruses have circulated in human and animal popu-
lations for many years and in humans they are a cause of 
respiratory tract infections [1]. More recently, severe acute 
respiratory syndrome coronavirus 2 emerged in Wuhan, 
China in December 2019 [2, 3]. Severe acute respira-
tory syndrome coronavirus 2 causes coronavirus disease 
(COVID-19) and this outbreak was declared a global pan-
demic by the World Health Organization in March 2020 
[4]. Fever, cough and shortness of breath are the main 
reported symptoms of COVID-19 [5] but this disease also 
has a concerning case mortality rate among certain popu-
lations, such as older adults and those with underlying 
health conditions.
In the current COVID-19 pandemic, there is a need to 
identify effective safe treatments as rapidly as possible. 
Lopinavir-ritonavir (LPVr) is a combination protease 
inhibitor and nucleoside analogue used for the treatment 
of human immunodeficiency virus (HIV) type 1 [6]. The 
use of LPVr in severe acute respiratory syndrome has been 
examined previously and indicated a favourable clinical 
response, with a decreased incidence of adverse clinical 
outcomes at day 21, reduced viral load at 48 h, decreased 
steroid use and reduced incidence of nosocomial infections 
[7]. For this reason, multiple trials in COVID-19 are cur-
rently being conducted to determine if LPVr is an effec-
tive treatment, including the worldwide RECOVERY trial 
and the World Health Organization’s SOLIDARITY trial 
[8–10]. It is essential to examine the benefit-risk profile 
of all medications, but ongoing monitoring is especially 
important where treatments may be used with limited evi-
dence in new indications. Lopinavir-ritonavir is already 
being used as a standard treatment for COVID-19 in some 
countries. Systematic reviews have been conducted to 
examine the efficacy of LPVr in the treatment of COVID-
19, though not all of these have been peer reviewed to 
date [11]; so far these have concluded that there is a lack 
of evidence of efficacy [11, 12]. However, a systematic 
benefit-risk assessment on the use of LPVr for COVID-19 
treatment, based on currently available evidence, has not 
yet been conducted.
The Benefit-Risk Action Team (BRAT) uses a struc-
tured descriptive framework to outline the key benefits 
and risks of a medication within a defined disease con-
text. If sufficient relevant data are available, an additional 
quantitative assessment can be used to further examine the 
benefit-risk profile [13]. The BRAT was also designed to 
assist communication with regulatory authorities [14]. The 
framework design allows for transparency in the decision-
making process and assumptions can be explored further 
by sensitivity analyses using quantitative methods [15]. 
This dynamic approach to a benefit-risk assessment of 
potential treatments for COVID-19 has been previously 
applied to the anti-viral agent remdesivir [16].
The systematic benefit-risk assessment for LPVr was con-
ducted based on publicly available data to 13 May, 2020. 
Because of continuous emerging data on the use of LPVr 
in COVID-19, the framework can be subsequently used to 
repeat the assessment as further data arise, allowing for rapid 
and dynamic evidence-based decision making as more rel-
evant data become available. This assessment was conducted 
to aid clinicians and public health and regulatory authorities 
in the decision-making process on treatments for COVID-19.
2  Objectives
This study aimed to examine the benefit-risk profile of LPVr 
in patients with COVID-19 compared to standard of care, 
placebo or other treatments. A key objective of this study 
was to provide a platform for a dynamic systematic benefit-
risk evaluation; although initially this evaluation is likely 
to contain limited information, it is required because of the 
urgent unmet public need. Importantly, it allows additional 
data to be incorporated as they become available, and re-
evaluation of the benefit-risk profile.
3  Methods
3.1  Benefit‑Risk Framework
The BRAT framework was used to assess the overall benefit-
risk of using LPVr as a treatment for COVID-19 compared 
to standard of care, placebo or other treatments. The BRAT 
uses a six-step iterative process to support the decision and 
communication of a benefit-risk assessment: define deci-
sion context, identify outcomes, identify data sources, cus-
tomise framework, assess outcome importance, and display 
and interpret key benefit-risk metrics [17]. Three settings 
of interest for use of COVID-19 treatments were identified; 
treatment for severe disease, treatment of mild disease in 
the community and prevention in healthcare profession-
als exposed to the virus. This assessment focuses on LPVr 
for the treatment of severe COVID-19 disease, which we 
defined as hospitalisation as a result of COVID-19 infection.
3.1.1  Population of Interest
Patients with COVID-19 who were treated with LPVr were 
the population of interest, while patients receiving standard 
of care, placebo or other treatments were the comparators of 
interest. Where standard of care was reported as the compar-
ator group, this refers to no use of a specific pharmaceutical 
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treatment for COVID-19 but provision of standard support-
ive therapy within the hospital setting.
3.1.2  Outcomes of Interest
All potential benefits and risks related to LPVr were initially 
identified, regardless of their importance. Key benefits and 
risks were selected by clinician judgement, i.e. those consid-
ered to be of clinical importance or potentially serious, and 
included in the value tree, which provides a visual represen-
tation of these outcomes in the context of severe COVID-19 
disease. These benefits and risks displayed in the value tree 
were ranked according to perceived importance (benefits) 
and potential seriousness (risks). Two clinicians performed 
this ranking after discussion of the importance of each ben-
efit and risk. Risks were categorised according to which sys-
tem organ class (SOC) they belonged to, and where multiple 
events were identified within the same SOC, the ranking was 
based on the most serious event(s) within that SOC, with the 
most serious event(s) in each SOC presented first.
3.1.3  Data Sources and Customisation of the Framework
A literature search was performed in PubMed and Embase 
using the following search strategy: (lopinavir AND ritona-
vir) AND (covid* OR SARS-CoV-2 OR n?CoV OR corona-
virus). Two reviewers examined articles for eligibility and a 
third clinical reviewer made the final decision on inclusion. 
Papers were included in the data extraction tables if they 
reported quantitative data on effectiveness and/or safety of 
LPVr in patients with severe COVID-19. Case reports and 
case series were excluded from the data extraction tables, 
but were considered for construction of the value tree. 
Results were restricted to English language only (abstracts 
in English language were acceptable where sufficient data 
provided) and peer-reviewed publications from 2019 to 13 
May, 2020. Data were extracted for each benefit and risk, for 
LPVr and the comparator (standard of care, placebo or other 
treatments), where available. EudraVigilance spontaneous 
reporting data (up to 8 May, 2020) for LPVr where used in 
COVID-19 were also examined. EudraVigilance data were 
examined because of the usefulness of identifying real-world 
reports of adverse events outside of the clinical trial setting 
and because the publicly available version of this specific 
data source is frequently updated. After data extraction, a 
second reviewer performed a quality-control check on the 
extracted data.
3.2  Outcome Assessment
Key benefits and risks associated with the use of LPVr 
were identified for inclusion in the value tree from available 
data sources, including the product information, regulatory 
assessment reports and published literature. Predicted key 
benefits (clinical endpoints) were derived from both the pub-
lished literature and in the case of ongoing studies, available 
clinical trial protocols. These benefits and risks, as presented 
in the value tree, were derived from both qualitative and 
quantitative data. A summary benefit-risk table was created 
to allow visualisation of the magnitude of each benefit and 
risk. Risk differences and corresponding 95% confidence 
intervals (CIs) were calculated for each outcome where both 
numerator (number of events) and denominator (number of 
patients at risk) were available for both the treatment group 
(LPVr) and comparator group. No appropriate compara-
tor groups were identified for LPVr within EudraVigilance 
owing to the recent nature of the pandemic and the lack 
of treatments made available for COVID-19 outside of the 
clinical trial setting. As such, adverse events reported for a 
comparison treatment in EudraVigilance were not available. 
Consequently, spontaneous reports are not included in the 
benefit-risk table and are presented in the text only.
Given the limited data at this point in time, further quanti-
tative assessment was not considered appropriate. However, 
such methods can be used to account for both the importance 
of outcomes and the size of the study from which data were 
extracted by weighting outcomes. In anticipation of using 
further quantitative methods in the future when further data 
are made available, we have ranked the outcomes in the 
value tree by considered clinical importance.
4  Results
Figure 1 displays the value tree of the key benefits and risks 
related to LPVr treatment in COVID-19, which was con-
structed using a wide variety of data sources.
4.1  Benefits
Key benefits have been listed in the value tree in descending 
order of perceived clinical importance. At the current time, 
only one clinical trial was identified that provided empirical 
data for any of the clinical endpoints listed in the value tree 
[18]. Whilst the primary objective of this clinical trial was 
time to clinical improvement, additional data were provided 
for various endpoints including mortality risk, risk and dura-
tion of invasive mechanical ventilation, risk of non-invasive 
ventilation and oxygen requirement.
4.2  Risks
Key risks were identified for LPVr based on the current 
available evidence. It is acknowledged that this product is 
not licenced for use in the treatment of COVID-19 disease, 
and whilst safety data are available for its licenced use in 
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HIV type 1, its safety profile in the context of COVID-19 is 
largely unknown. Furthermore, for the limited safety data 
that are available for its use in COVID-19, it is often unclear 
whether the reported adverse event is due to the use of LPVr, 
or attributable to the underlying disease. Potentially serious 
risks that are likely to still pose a risk with the proposed 
short-term use of LPVr for COVID-19 have been summa-
rised in the value tree and ranked according to perceived 
seriousness.
One of the most serious risks is prolongation of the QT 
interval, and the subsequent increased risk of sudden car-
diac death [19–22]. Patients with COVID-19 are already 
predisposed to the development of cardiac arrhythmia owing 
to the effect of the virus on metabolic dysfunction, myo-
cardial inflammation and the sympathetic nervous system 
[20]. Additionally, it is important to note that LPVr is an 
inhibitor of cytochrome P450 3A4, and therefore it cannot be 
used with other medicines that are substrates of this enzyme, 
such as chloroquine, which itself can cause QT prolongation 
[21]. In addition to the effects on QT prolongation, LPVr 
has also been shown to cause modest asymptomatic pro-
longation of the PR interval in some healthy adult subjects, 
with rare reports of second- or third-degree atrioventricular 
block in patients with underlying structural heart disease and 
pre-existing conduction system abnormalities or in patients 
receiving drugs known to prolong the PR interval (such as 
verapamil or atazanavir), and therefore LPVr should be used 
with caution [23] in such patients.
Lopinavir/ritonavir are both inhibitors of the cytochrome 
P450 3A isoform, and therefore treatment is likely to 
Death All-cause mortality – Risk and time to death 
ICU admission – invasive mechanical ventilation and/or ECMO, duration, time to ICUClinical endpoints
1
Nervous System - Cerebrovascular accident, encephalopathy, convulsion, dysgeusia, ageusia, tremor, peripheral neuropathy  
Hepatic- injury, hepatitis including AST, ALT and GGT increases, cholecystitis, fatty liver, cholangitis  
Gastrointestinal – pancreatitis, haemorrhage of lower digestive tract, enterocolitis, acute gastritis, ulcer 
Benefits
Risks 1
Benefit-Risk 
Balance
Surrogate endpoints Viral load parameters - Clearance rate (throat, sputum, nasopharyngeal swabs)  
Other clinical outcomes – time to  improvement or recovery, duration of hospitalisation
Renal – acute kidney injury, nephritis, reduced creatine clearance, kidney stones  
Respiratory - ARDS, upper respiratory tract infection 
Non-invasive ventilation / High Flow oxygen - duration, time to ventilation   
Immune system - hypersensitivity including urticaria and angioedema 
Blood – severe anaemia, leucopenia/neutropenia, lymphadenopathy, thrombocytopenia   
Cardiac - QT prolongation, pulmonary oedema , vasculitis, bradycardia, MI, AV block, tricuspid valve incompetence, hypertension
Venous thromboembolism – deep vein thrombosis  
Skin - Stevens-Johnson syndrome, erythema multiforme, severe cutaneous eruption 
Oxygen - Number of patients requiring supplemental oxygen, duration 
1Both benefits and risks have been ranked according to perceived clinical significance. Risks have been categorised according to system organ class (SOC). The SOCs have been ranked based on the most serious events/events within each system, which have 
been presented first; ECMO=Extra Corporeal Membrane Oxygenation; ICU=Intensive Care Unit; ARDS=Acute Respiratory Distress Syndrome; AST=Aspartate aminotransferase; ALT=Alanine aminotransferase; GGT=Gamma-glutamyl transpeptidase
Lopinavir/ritonavir acts as a CYP3A4 inhibitor resulting in clinically significant drug interactions Drug Interactions
Fig. 1  Value tree of key benefits and risks identified for lopinavir/
ritonavir, ranked by order of clinical significance. Superscript 1: both 
benefits and risks have been ranked according to perceived clinical 
significance. Risks have been categorised according to system organ 
class. The system organ classes have been ranked based on the most 
serious events/events within each system, which have been presented 
first. ALT alanine aminotransferase, ARDS acute respiratory distress 
syndrome, AST aspartate aminotransferase, CYP cytochrome P450, 
ECMO extracorporeal membrane oxygenation, GGT gamma-glutamyl 
transpeptidase, ICU intensive care unit, MI myocardial infarction
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increase plasma concentrations of concomitant medicinal 
products that are primarily metabolised by cytochrome P450 
3A [23]. Clinically significant drug interactions have been 
observed with LPVr use during treatment for COVID-19, 
including increased plasma concentrations of direct oral 
anticoagulants [24], and increased plasma concentrations 
of immunosuppressants in organ transplant recipients [25].
Certain risks factors and clinical characteristics have been 
associated with the development of acute respiratory distress 
syndrome (ARDS) amongst patients with COVID-19 [26]. 
Patients who developed COVID-19-related ARDS were 
likely to require admission to the intensive care unit. In the 
study by Cao et al., respiratory failure/ARDS was reported 
as a serious adverse event in both treatment groups [18]. 
Whilst causality in these cases is not known, it would seem 
likely that these cases were attributable to progression of the 
underlying COVID-19 disease.
Hypersensitivity reactions such as urticaria and angi-
oedema are reported to occur commonly with the use of 
LPVr for the treatment of HIV, and rarely serious skin reac-
tions such as Stevens–Johnson syndrome and erythema mul-
tiforme have been reported with its use in this treatment 
population [23]. Gastrointestinal side effects of LPVr are 
well recognised, and diarrhoea and nausea are very com-
mon. Serious gastrointestinal adverse effects included in 
the key risks for this assessment include pancreatitis, which 
has been associated with the use of LPVr [7, 23, 27]; most 
patients who developed pancreatitis during treatment for 
HIV had a prior history of this condition. Treatment with 
LPVr has been associated with an increase in triglycerides 
in patients treated for HIV [23], and amongst patients treated 
for COVID-19 [28–31], which is likely to be another con-
tributory factor in the development of pancreatitis.
In the context of treatment for HIV, LPVr has been 
uncommonly associated with certain adverse renal out-
comes, including a reduction in creatine clearance, nephritis 
and haematuria [23]. Cases of acute kidney injury have been 
reported in patients taking LPVr in COVID-19; however, 
it is unclear whether there is any association, as this out-
come was reported more frequently amongst patients in the 
standard of care comparator group [18] in addition to overall 
limited safety data availability. Elevations of liver enzymes 
have also been commonly reported with the use of LPVr in 
the treatment of HIV [23], and liver injury has been reported 
in patients treated with LPVr for COVID-19 [32, 33]. Blood 
dyscrasias have also been associated with the use of LPVr 
during HIV treatment [23], with reports of severe anaemia 
amongst patients treated for COVID-19 [18].
4.3  Quantitative Data
Data for outcomes are presented in the data extraction 
table and key benefit-risk summary table (Tables 1 and 2, 
respectively). From literature searching, we identified 143 
papers from PubMed and 264 papers from Embase for LPVr. 
All papers were reviewed for information on the benefits 
and risks relating to LPVr, including both quantitative and 
qualitative data. After initial review and removal of dupli-
cates, 43 papers were identified with information on safety 
of LPVr and 15 papers with efficacy information for LPVr. 
These papers were reviewed further to determine whether 
they met all inclusion criteria; seven papers were included 
in the final benefit-risk assessment.
In comparison to standard of care, data for several key 
benefits and risks for LPVr were identified. In the Cao et al. 
trial [18], the benefit of time to clinical improvement (inten-
tion-to-treat analysis) was not statistically significant after 
adjustment for other covariates in comparison to standard of 
care (16 vs 16 days, hazard ratio = 1.31, 95% CI 0.95–1.80). 
Other non-significant benefit data were identified in this trial 
including median duration of mechanical ventilation (risk 
difference = − 1 day, 95% CI − 4 to 2) and death at 28 days 
(risk difference = − 0.06, 95% CI − 0.17 to 0.06).
Risk data were mainly available from the Cao et al. trial, 
which reported fewer serious adverse events in patients tak-
ing LPVr (20%) compared to standard of care (32%). There 
were fewer cases of ARDS with LPVr compared to standard 
of care (13% vs 27%). The difference in the proportion of 
adverse events between groups was not tested statistically 
in the study and the study was also not powered to detect 
differences in adverse events.
Limited data were available for comparison of LPVr to 
other treatments. Viral clearance at day 14 for LPVr was 
lower compared with arbidol (85% vs 91%), and there 
was minimal difference in mean time to viral clearance 
(10.20 days vs 10.11 days, respectively). Data were only 
available for one risk in comparison to arbidol; a lower 
proportion of those patients treated with LPVr experi-
enced increased ALT compared with arbidol (9% vs 19%, 
respectively).
In spontaneous reports from Eudravigilance, for LPVr 
used in COVID-19, there were 28 reports of hepatocellu-
lar injury, 15 reports of acute kidney injury, 17 reports of 
prolongation of the QT interval, six reports of ARDS and 
three reports of pancreatitis. Information on case reports was 
only available from the publicly available dataset and thus 
was limited; however, these data are useful in identifying 
real-world reports of adverse events outside of the clinical 
trial setting.
5  Discussion
The study aim was to examine the benefit-risk profile of 
LPVr in COVID-19 patients compared to standard of care, 
placebo or other treatments. A key objective of this study 
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was to provide a platform for a dynamic systematic benefit-
risk evaluation; although initially this evaluation is likely 
to contain limited information, it is required because of the 
urgent unmet public need. Importantly, it allows additional 
data to be incorporated as they become available, and re-
evaluation of the benefit-risk profile. This paper provides a 
systematic benefit-risk assessment using the BRAT meth-
odology and is inclusive of the available literature up to and 
including 13 May, 2020. Therefore, this represents a snap-
shot of the data available to date and outlines a clear and 
transparent framework into which subsequent clinical trial 
and observational study data can be incorporated, and the 
benefit-risk profile re-assessed.
At the current time, data relating to the benefits of LPVr 
are limited, with efficacy data for clinical endpoints avail-
able from only one published clinical trial. This trial found 
no statistically significant difference in the primary outcome 
of time to improvement (intention-to-treat analysis) between 
the two groups (LPVr treatment in addition to standard sup-
portive care vs standard care alone); however, the sample 
size was small. There was some evidence (though not sta-
tistically significant) that LPVr reduced mortality at 28 days 
(95% CI 19.2% vs 25.0%), difference of -5.8% (95% CI -17.3 
to 5.7). It is of note that the median time interval between 
symptom onset and randomisation was 13 days (interquartile 
range, 11–16 days), therefore it is unknown whether more 
favourable results may have been seen if drug treatment had 
been initiated earlier in the course of the disease.
The safety profile of LPVr in the treatment of severe 
COVID-19 disease is largely unknown. We identified key 
risks from its usage in the treatment of HIV, in addition to 
the limited safety data available from its use in COVID-19. 
Comparator safety data revealed a lower incidence of all 
serious adverse events amongst patients receiving LPVr 
compared with standard of care (risk difference − 123 
events per 1000 patients). Very small numbers of cases 
of some adverse events were reported in the study by Cao 
et al., including severe anaemia, acute gastritis and lower 
gastrointestinal bleeding, all of which were only reported 
amongst patients taking LPVr. The incidence of acute 
kidney injury was lower in the Cao et al. trial amongst 
patients taking LPVr compared with standard of care (3% 
vs 6%). The incidence of ARDS was also observed to be 
lower in patients using LPVr compared with standard of 
care (13% vs 27%). It is acknowledged that ARDS is a 
known outcome in COVID-19 and thus a reduction in risk 
could potentially be considered a benefit of LPVr treat-
ment. Acute respiratory distress syndrome is included as 
a risk in the current value tree because it was considered 
an adverse event in all trials examined; however, the ben-
efit-risk assessment may be updated if sufficient evidence 
becomes available to suggest it should be considered a 
benefit instead. Consequently, the incidence of ARDS with 
LPVr in COVID-19 should be intensively monitored as 
further data are made available to determine if this could 
potentially be a benefit of treatment.
Table 2  Benefit-risk summary table for key benefits and risks identified for lopinavir-ritonavir (L/R) compared to standard of care
CI confidence interval, GI gastrointestinal, RD risk difference
a 95% CI calculated by authors and not provided in the original manuscript
Outcome name L/R risk/1000 
patients
Standard of care 
risk/1000 patients
RD (95% CI)/1000 patients Hazard ratio (95% CI)
Benefits
 Death at 28 days 192 250  − 58 (− 173, 57)
 Invasive mechanical ventilation at day 14 30 50  − 20 (− 75, 36)a
 Non-invasive ventilation at day 14 51 60  − 9 (− 75, 56)a
 Time to clinical improvement 1.31 (0.95, 1.80)
 Clinical improvement at day 28 788 700 88 (− 33, 209)
 Supplemental oxygen at day 14 253 200 53 (− 80, 185)a
 Viral load parameters: viral clearance at day 14 853 765 88 (− 431, 607)
Risks
 Prolonged QT interval 11 0 11 (− 10, 31)a
 Acute heart failure 0 10  − 10 (− 30, 10)a
 Acute respiratory distress syndrome 126 273  − 147 (− 272, − 21)
 Acute kidney injury 32 61  − 29 (− 89, 31)a
 Severe anaemia 32 0 32 (− 4, 67)a
 Acute gastritis 21 0 21 (− 8, 50)a
 Haemorrhage lower GI tract 21 0 21 (− 8, 50)a
 Any serious adverse event 200 323  − 123 (− 267, 20)a
Benefit-Risk of Lopinavir-Ritonavir in COVID-19
Overall, there was a lack of efficacy data with no clear 
benefits identified for LPVr treatment compared with stand-
ard of care. Risk data, although limited, suggested a pos-
sible decrease in adverse events for some serious outcomes 
compared to standard of care. Further data are needed on 
the efficacy and effectiveness of LPVr for severe COVID-
19. An update to this dynamic benefit-risk assessment will 
be published when sufficient data are made available from 
further peer-reviewed studies that impact significantly on the 
benefit-risk of LPVr.
5.1  Strengths and Limitations
A strength of this approach is the inclusion of all key ben-
efits and risks in the same model and a transparent frame-
work into which further data can be included as and when 
these become available. The method has a significant advan-
tage compared with systematic reviews, which are equally 
comprehensive but focus only on efficacy or safety, rather 
than considering both together. When sufficient data are 
available, the methodology allows benefits and risks to be 
ranked, and weightings applied based on this ranking, with 
further quantitative analysis. The reproducibility of this 
assessment allows multiple treatments to be assessed using 
this approach, thereby allowing direct comparison between 
different treatments. This is of great significance during the 
current COVID-19 crisis, in which several potential inter-
ventions currently under evaluation need to be assessed and 
evaluated in real time, and where new data need to be incor-
porated quickly. Regulatory decision makers are also famil-
iar with this framework, facilitating interpretation.
A limitation of the benefit-risk assessment presented at 
this time is the relative paucity of data that has been included 
in the model, as many clinical trials assessing LPVr are still 
ongoing. In addition, trials for which data were available had 
very small sample sizes and were likely to be underpowered 
when examining non-primary outcomes. Causality cannot 
be confirmed for many outcomes at this point in time but in 
general there is a need for further data regarding outcomes 
in COVID-19. It is anticipated that such data will become 
available in due course and allow us to comment further on 
the causal association between LPVr and outcomes included 
in the value tree. The dynamic nature of this benefit-risk 
assessment allows further updates in the future if sufficient 
data are made available to significantly impact the conclu-
sion of the benefit-risk assessment.
Study quality was not considered in the assessment, 
although we only included peer-reviewed articles. The 
importance of each benefit and risk was assessed by two 
physicians and ranked accordingly based on their clinical 
judgement. Because of the dynamic nature of the benefit-risk 
assessment, other experts could be engaged in the future to 
reassess the importance of the benefits and risks and revise 
the value tree. Outcomes displayed in the value tree were 
identified from a variety of sources and may therefore be 
related to different underlying diseases with different man-
agement including potentially different doses of LPVr. 
Efficacy outcomes could also be dependent on the time of 
administration of LPVr. Further, while we defined standard 
of care as no use of a specific pharmaceutical treatment for 
COVID-19 but provision of standard supportive therapy 
within the hospital setting, we acknowledge that standard 
of care may vary by setting and country.
6  Conclusions
Based on currently available data, there was no clear ben-
efit for use of LPVr compared to standard of care in severe 
COVID-19. Risk data suggested a possible decrease in seri-
ous adverse events. There was a reduction in ARDS with 
LPVr in one study. Overall, the benefit-risk profile for LPVr 
in severe COVID-19 cannot be considered positive until fur-
ther efficacy and effectiveness data become available.
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